Celldex Therapeutics (CLDX) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about CLDX filings

Are insiders buying or selling Celldex Therapeutics Inc (CLDX) stock?

Neither. Celldex Therapeutics Inc (CLDX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded CLDX recently?

None. No member of Congress disclosed a CLDX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CLDX smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

21 funds hold a position.

Questions about CLDX filings

Are insiders buying or selling Celldex Therapeutics Inc (CLDX) stock?

Neither. Celldex Therapeutics Inc (CLDX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded CLDX recently?

None. No member of Congress disclosed a CLDX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CLDX smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$141.4MSells/Trims$98.1M

Buys/Adds (1)

FM
FMR LLC
Q3 2026 13F
$141.4M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (1)

P7
Point72
Steven Cohen · Q2 2026 13F
$98.1M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 3.4% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.96+3.39% beat

-$0.99 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$1.03

-$1.07 to -$0.96

Revenue expected

$1.2M

10 analysts

Last 30 days

5up1down

Analysts raising estimates

Estimate drift

0.02

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$0.96est. -$0.99	+3.39%beat	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 6, 2026	-$0.94est. -$1.06	+11.41%beat	$22.0KSEC filing	-97.0%from $730.0K
Mar 31, 2026Reported May 7, 2026	-$1.18est. -$1.13	-4.22%miss	$15.0KSEC filing	-97.8%from $695.0K
Dec 31, 2025Reported Feb 25, 2026	-$1.22est. -$1.00	-22.50%miss	$121.0KYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 10, 2025	-$1.01est. -$0.89	-13.48%miss	$1.4M · 9MSEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 7, 2025	-$0.85est. -$0.86	+1.16%beat	$730.0KSEC filing	-70.8%from $2.5M
Mar 31, 2025Reported May 8, 2025	-$0.81est. -$0.74	-9.46%miss	$695.0KSEC filing	+345.5%from $156.0K
Dec 31, 2024Reported Feb 27, 2025	-$0.71est. -$0.71	+0.64%in line	$7.0M · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $29.72
High: $30.01
Low: $28.46
Prev close: $30.15
52-wk high: $45.14
52-wk low: $22.33
Mkt cap: $2.37B
ROE: -49.5%
Beta: 1.03
P/S: 14988.2x
P/B: 3.7x
Profit margin: +0.0%
Op margin: -211685.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.4B

Valuation

P/S14988.18
P/B3.71

Quality

Operating margin-211685.0%
ROE-49.5%
ROA-30.5%

Growth

Beta1.03

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

47balanced

20D volatility

57%annualized

52-week range

$28.53

$22.33$45.14

20D support

$27.46recent floor

20D resistance

$31.71recent ceiling

Returns

5D +0.9%20D -1.4%60D -31.6%

Price vs moving averages

SMA20 -3.6%SMA50 -11.4%SMA200 -13.1%

Volume pace

0.40xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

-$0.96est. -$0.99

+3.39%

$0.00Yahoo Finance

No year-ago quarter

Jun 30, 2026Aug 6, 2026

-$0.94est. -$1.06

+11.41%

$22.0KSEC filing

-97.0%from $730.0K

Mar 31, 2026May 7, 2026

-$1.18est. -$1.13

-4.22%

$15.0KSEC filing

-97.8%from $695.0K

Dec 31, 2025Feb 25, 2026

-$1.22est. -$1.00

-22.50%

$121.0KYahoo Finance

No year-ago quarter

Sep 30, 2025Nov 10, 2025

-$1.01est. -$0.89

-13.48%

$1.4M · 9MSEC filing

No year-ago quarter

Jun 30, 2025Aug 7, 2025

-$0.85est. -$0.86

+1.16%

$730.0KSEC filing

-70.8%from $2.5M

Mar 31, 2025May 8, 2025

-$0.81est. -$0.74

-9.46%

$695.0KSEC filing

+345.5%from $156.0K

Dec 31, 2024Feb 27, 2025

-$0.71est. -$0.71

+0.64%

$7.0M · FYSEC filing

No year-ago quarter

Celldex Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about CLDX filings

Questions about CLDX filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 3.4% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Celldex Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about CLDX filings

Questions about CLDX filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 3.4% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Celldex Therapeutics Inc

Overview

Questions about CLDX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Celldex Therapeutics Inc

Overview

Questions about CLDX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.